galileo logo
The Company
management team
board of directors
the technology
the market
News
Employment
Contact
Home

Board of Directors

Douglas W. Lehrman

Mr. Lehrman has served as Director since July 2000. Mr. Lehrman is Managing Director at North Castle Partners, LLC in Greenwich, Connecticut. For 17 years prior to founding North Castle with his partners in 1998, Mr. Lehrman was an investment banker specializing in leveraged buyouts.  During that career he was involved with over 50 transactions with a total value of approximately $8 billion. Much of Mr. Lehrman's focus was developing new sources of private capital for growth-oriented companies to achieve their business plans. His focus at North Castle includes Grand Expeditions, its global travel company, a variety of early stage investments including Galileo Laboratories, and Healthnotes, in addition to opportunities in the food, health information and other sectors.

Craig C. Taylor

Mr. Taylor has served as  Director since January 1998. Mr. Taylor is a General Partner of Alloy Ventures, formerly Asset Management, and partner of AMC Partners 89, L.P. Mr. Taylor has been with Asset Management, a venture management group, since 1977. Mr. Taylor is currently a Director of Telor Ophthalmic Pharmaceuticals, Inc., Metra BioSystems, Inc., Lynx Therapeutics, Inc., Pharmacyclics, Inc. and of several private companies. Mr. Taylor holds BS and MS degrees in physics from Brown University and an MBA from Stanford University Graduate School of Business.

Roger Salquist

Mr. Salquist has served as Director since May 1999. Mr. Salquist is a Partner and Managing Director of Bay City Capital ("BCC"), a San Francisco-based merchant bank. BCC is the Advisor and Mr. Salquist is the Chief Investment Officer of the North American Nutrition and Agribusiness Fund, which invests in high-growth-potential companies engaged in technological and business innovation in the nutrition and agribusiness sectors. From 1984 through 1996, Mr. Salquist served as Chairman and Chief Executive Officer of Calgene, Inc. Mr. Salquist currently serves as a Director of Akkadix Corporation, Lifespring, and OmegaTech, Inc. Mr. Salquist is a trustee of the Fidelity Investments Charitable Gift Fund and a member of the Board of Trustees of the University of San Francisco. Mr. Salquist holds a BA and an MBA from Stanford University.

Richard A. Miller, MD

Dr. Miller has served as  Director since January of 1998. Dr. Miller is the President, Chief Executive Officer and a Director of Pharmacyclics, Inc., a public biotechnology company, which he co-founded in April 1991. In 1984, Dr. Miller co-founded IDEC Pharmaceuticals Corporation, a public biotechnology company, where he served as Vice President and a director until February 1992. Dr. Miller also is Clinical Professor of Medicine (Oncology) at Stanford University Medical Center. Dr. Miller received his MD, summa cum laude, from the State University of New York Medical School and is board certified in both Internal Medicine and Medical Oncology.

Terry Gould

Mr. Gould has served as Director since January 1998. Mr. Gould is Executive Director, Direct Investment Team at UBS Brinson. Prior to joining UBS Brinson, Mr. Gould was with Trinity Ventures, Ltd. Earlier in his career, Mr. Gould spent five years as a management consultant, including at the Boston and San Francisco offices of the Boston Consulting Group Inc., an international strategy-consulting firm. Mr. Gould also was a founder of and manager in two successful, entrepreneurial companies, Innovative Leisure and Viasoft. Mr. Gould currently is a Director of Allegis Corporation (formerly Net-It Software) and Network Integrity, Inc. Mr. Gould holds a BA from Dartmouth College and an MBA from the Stanford University Graduate School of Business.

Vicente Anido, PhD

Dr. Anido has served as Director since December 1998. Most recently he served as Chief Executive Officer of CombiChem, Inc. Prior to CombiChem, Inc., Dr. Anido was the President of the Americas Region at Allergan, Inc., where he was responsible for the company's commercial operations in North and South America. Prior to Allergan, Dr. Anido spent approximately 18 years at Marion Laboratories and Marion Merrell Dow. Dr. Anido holds BS and MS degrees in pharmacy and pharmaceutical sciences from West Virginia University and a PhD from the University of Missouri.

Guy Miller, MD, PhD

Dr. Miller, founder and Chief Executive Officer of Galileo Laboratories, serves also as Chairman of the Board of Directors. Before forming Galileo, Dr. Miller was Associate Professor at Johns Hopkins Medical Institutions School of Medicine. After completing a Surgical Internship at the University of Chicago, he completed a residency in Anesthesiology & Critical Care Medicine and a Fellowship in Multidisciplinary Critical Care Medicine at Johns Hopkins. Currently, Dr. Miller is Clinical Instructor, Stanford University School of Medicine. Dr. Miller holds an MD from the Medical College of Pennsylvania and a PhD in Chemistry from the University of Virginia.

 

Valsartan 40 mg cost


Generic Valsartan Launch
4-5 stars based on 554 reviews

Valsartan generic equivalent was an effective antidepressant. A randomized, placebo-controlled trial was conducted to evaluate the safety and effectiveness of generic brand-name versions Sertraline Injection, both at dosages of 20 mcg to 40 mcg. Trial Outcomes Primary Outcome The primary outcome measure was change in depression score obtained at baseline. Secondary outcomes included change in Hamilton Depression Rating Scale total score, change in Hamilton Rating Scale for Clinical Improvement (HRSD-C) total score, dropouts, and number of patients in the two groups. The primary outcome measure at 2-week point was a 2-item scale (1=not at all, to 15=extremely) asking patients what they felt were helpful features and/or adverse effects of Sertraline. This survey was administered by trained and certified questionnaire takers who were unaware of trial allocation. The drug store sodo seattle second survey was administered at the final baseline. Each patient was interviewed by two study investigators, who were blinded to trial group assignment. A score was obtained, which could be either 0 (not reporting any adverse effects) or 1 (reporting any adverse effects), from a Likert scale with minimum of 10 points. The investigators then calculated a standardized mean difference [SMD] from baseline in the two groups (0.2). The trial was stopped early if either the primary or secondary outcomes failed to reach statistical significance. Assessments Determinations of patients randomized in the two groups were based on medical chart review, a completed computerized diagnostic interview, and/or a physician's interview with each patient the diagnosis of depression. All patients, with age and baseline depression scores, were eligible for inclusion in the analysis. Patients with a history of drug dependence at baseline were excluded. characteristics summarized on the basis of patient self-report and interview data. Patients with concomitant psychotropic drug treatment were excluded. The study protocol stipulated that each patient be followed for a minimum of 3 weeks. This time period was set through a computer-assisted telephone interview. Patients in both groups continued receiving their antidepressant treatment (ie, Sertraline injection 2 mg or placebo) during this time period. Additional information to guide the patient care was obtained from physicians, who conducted a medical chart review, completed interviews, and collected data Can you buy promethazine over the counter in the uk on all medications used. Trial Outcomes After completing the survey, participants were enrolled into a 2-week run-in period (ie, the time between study entry and the 3-week measurement of primary endpoint). Patients randomized to Sertraline injection were also encouraged to initiate Sertraline injection at 3 mg within to 4 weeks after randomization. At this time point, participants were also monitored for response by using a change from baseline Valsartan 10mg $181.27 - $1.01 Per pill to treatment response. Patients randomized placebo were encouraged to continue taking placebo. At every visit for the 2 months after 2-week run-in period, the following items were completed to assure that no changes baseline characteristics, treatment assignment, medication, Online pharmacy clomid uk or health status existed during the 2 months: 1. Drug and alcohol abuse/dependence current medication use At entry to the study, drug and alcohol abuse/dependence were assessed by physicians using the Structured Clinical Interview for DSM-IV axis I disorders (SCID). Participants who had recently been treated with an antidepressant or stimulant (as indicated by the presence or absence of a drug screen) prior to study entry had been added to the "recent antidepressant" category and were excluded.

  • Velbert
  • Bad Wimpfen
  • Meisenheim
  • Borgholzhausen
  • Crailsheim


Valsartan 30 Capsules 15mg $139 - $4.63 Per pill
Valsartan 90 Capsules 10mg $240 - $2.67 Per pill



Can you buy voltarol over the counter Where can i buy sildenafil citrate over the counter Prednisone online buy Buy propranolol uk online


WiltonGorhamValsartan Bass Lake
BellwoodRanchOberhof
EloyValsartan MeadowValsartan Woodland
valsartan generico preço
diovan generic valsartan
cost of valsartan 160 mg

Acetazolamide generic price | Avodart generic cost | Dapoxetine buy online canada | Actoplus met generic


  1. drug store in honolulu
  2. drug store delivery los angeles
  3. generic valsartan vs diovan
  4. what is the cost of valsartan
  5. generic valsartan cost
  6. generic for valsartan
  7. diovan generic valsartan


Valsartan generic for diovan alolone acetonide in chronic heart failure. Anticancer Res. 10, 1578–1584 (1987). 65. Fekadu-Anuar, D, O'Sullivan, J E and Thompson, F Jr: Diastolic pressure and blood response to high-dose aspirin and beta-blockers. JAMA 269, 1385–1389 (1984). 66. Shukla, R, Singh, A R and Chaudhry, U K.: Effect of β-blockers on serum potassium and urinary sodium in diabetic hypertension: is the relationship between potassium and sodium controlled? Diabetologia 29, 825–828 (1988). 67. Goyeneche, M I, Zaytoun, C and Douds, P T Jr: The effect of beta-blockers on insulin secretion and the renal function in patients with type 2 diabetes. Diabetes Care 13, 1587–1592 (1990). 68. Stolerman, J: The effect of drug therapy on plasma potassium. Diabetes Care 8, 1597–1602 (1980). 69. Tachir, K, Fiala, M and Sperlich, D: Effect of paracetamol treatment on potassium excretion in type 2 diabetic patients with hyperkalaemia. Diabetes Care 14, 927–931 (1981). 70. Stolerman, J: The effect of paracetamol on excretion potassium and the renal function schwietermans drug store inc new bremen united states in type 2 diabetic patients. Part I: Serum potassium. Diabetes Care 14, 1126–1128 (1981). 71. Fiala, M and Stolerman, J: Effect of paracetamol treatment on potassium excretion in type 2 diabetic patients with hyperkalaemia. Part II: Urinary excretion of potassium. Diabetes Care 14, 1197–1202 (1981). 72. Stolerman, J: The effects of paracetamol in hypokalaemic diabetic patients with hyperkalaemia: results of a randomized controlled is valsartan generic for diovan trial. Diabetes Care 12, 721–726 (1978). 73. Naughton, D and Gaughan, J: Blood-level study of the effect paracetamol and other anti-diabetic agents on the plasma concentration of potassium and salt. Diabetes 18, 1829–1838 (1982).